Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 4atezolizumab 2Topotecan 2Paclitaxel 2Nivolumab 2Etoposide 2veliparib 1tocilizumab 1tislelizumab 1temsirolimus 1surufatinib 1sargramostim 1pentetreotide 1pembrolizumab 1niraparib 1iadademstat 1entinostat 1durvalumab 1dostarlimab 1cabozantinib 1budigalimab 1berzosertib 1belinostat 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1Sirolimus 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × iadademstat × Endocrine × Clear all
NCT05420636 2025-07-30

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Fox Chase Cancer Center

Phase 2 Terminated
20 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡